Kiora Pharmaceuticals (KPRX) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025 and an update on clinical development progress. The press release is included as Exhibit 99.1.
The company stated the information under Item 2.02, including Exhibit 99.1, is furnished, not filed, and will not be incorporated by reference into other filings unless specifically stated. Kiora’s common stock trades on NASDAQ under the symbol KPRX.
Kiora Pharmaceuticals (KPRX) filed its Q3 2025 Form 10‑Q, showing a small quarterly net income of $26,806, driven by lower operating expenses from collaboration credits and a reduction in contingent consideration fair value. For the nine months, the company recorded a net loss of $4,318,633.
Liquidity remained solid with Cash and Cash Equivalents of $5,508,899 and Short‑Term Investments of $13,866,546. Management states these resources are sufficient to fund planned operations into late 2027. Total assets were $29,863,454 and total liabilities were $7,452,712.
Operating expenses in the quarter benefited from Collaboration Credits of $(1,658,248) and a Change in Fair Value of Contingent Consideration of $(1,721,033), offsetting R&D and G&A. The balance sheet includes Deferred Collaboration Revenue of $1,250,000 tied to an option agreement with Senju.
The company highlighted its TOI license executed in 2024 and ongoing ABACUS‑2 activities. Common shares outstanding were 3,433,491 as of September 30, 2025, and 3,677,935 as of November 5, 2025.
Kiora Pharmaceuticals, Inc. filed a shelf registration on Form S-3 to offer up to $100,000,000 of common stock, preferred stock, warrants, debt securities and/or units. The prospectus describes the company as a clinical-stage ophthalmic biotech developing KIO-301 (a photoswitch for late-stage vision loss such as retinitis pigmentosa), KIO-104 (an intravitreal DHODH inhibitor for retinal inflammatory diseases) and KIO-101 (a topical formulation related to KIO-104). Kiora completed a Phase 1b for KIO-301 and entered a strategic license with Théa Open Innovation providing $16 million upfront, potential milestones up to $285 million and tiered royalties up to the low 20% range; ABACUS-2 (Phase 2) enrollment began in 2Q 2025. KIO-104 Phase 1b/2a showed reductions in intraocular inflammation and edema and a Phase 2 trial began enrollment in 2Q 2025. The company reports orphan designations from FDA and EMA for KIO-301, states its common stock trades on Nasdaq under KPRX and discloses cash and short-term investments expected to fund operations into late 2027, while noting it will need additional financing and that its smaller reporting company status allows reduced disclosure.